Leadership Team
Meet our experienced team.
Don’t miss our poster presentation “Real-time live cell imaging in successful antibody drug conjugate development” or our featured talk on Day 2 of the conference, “ADC Design, Validation, and Optimization to Enhance Their Therapeutic Potential,” on Thursday, March 14th, at 11:30 AM. We will also be participating in the partnering meetings, so make sure to schedule one with our team today.
Day 2 presentation: “Stage appropriate bioassays for the successful development of ADCs” presented by Rob Holgate, VP of Research & Innovation and Erika Kovacs, Sr. Dir. of Bioassays at Abzena
Antibody-Drug Conjugates (ADCs) have rapidly become an important class of targeted therapeutics against cancer, delivering both the specificity of mAbs and the cytotoxicity of small molecule drugs.
Bioassays are a fundamental component of drug development and allow the assessment of a wide variety of properties from basic functionality and mechanism of action through to assessment of immunogenicity risk and safety. As the diversity of both ADCs and bioconjugates in general expands, choosing the most appropriate assay format at the most appropriate phase of development becomes of utmost importance.
Poster title: “Real-time live cell imaging in successful antibody-drug conjugate development”
Abstract:
Antibody Drug Conjugates (ADCs) have rapidly become an important class of targeted therapeutics against cancer, delivering both the specificity of mAbs and the cytotoxicity of small molecule drugs.
Continual developability underpins all aspects of ADC drug discovery and development and the appropriate use of real- time live cell imaging as part of the developability assessment of ADCs can play a significant role in the selection of candidates with the greatest chance of clinical success.
Events Details:
Dates: March 13-15
Location: Novotel London West, 1 Shortlands, Hammersmith International Ctre, Hammersmith, W6 8DR, London, UK
Event Website: Homepage – Biologics 2024 (oxfordglobal.com)